Juno Therapeutics Profile

86.96
null 0.00  0.00%
0%
0%

Disposition of 125000 shares by Bernard Cassidy of Juno Therapeutics subject to Rule 16b-3

Juno Therapeutics insider trading alert for disposition of employee stock option (right to buy) by Bernard Cassidy, General Counsel & Secretary, on May 5, 2018. This event was filed by Juno Therapeutics Inc with SEC on 2018-03-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Juno Therapeutics Summary

Juno Therapeutics (JUNO) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 589 people. Juno Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 10.1 B. Juno Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 116.11 M outstanding shares of which 8.19 M shares are currently shorted by private and institutional investors with about 3.36 trading days to cover. currently holds about 927.53 M in cash with (201.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.18.
Check Juno Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 86.96HorizonTargetOdds Above 86.96
?%30 days 86.96 ?%
Based on normal probability distribution, the odds of Juno Therapeutics to move above current price in 30 days from now is about 0.0% (This Juno Therapeutics probability density function shows the probability of Juno Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Glenmede Trust Co NaCommon Shares1567 K
Omega Fund Management LlcCommon Shares0.00.0
View Juno Therapeutics Diagnostics

Selected Juno Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Juno Therapeutics Against Markets

Current Ratings

Juno Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
30 
Equity ratings for Juno Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 589 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameJuno Therapeutics
CEOHans BishopView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationWASHINGTON, U.S.A
Business Address400 Dexter Avenue North
ExchangeNASDAQ
CIK Number01594864.0
CUSIP48205A109
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.junotherapeutics.com
Contact Number206 582 1600
Currencynull

Recommendations

Juno Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
35.89Hold9Odds
Juno Therapeutics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Juno Therapeutics Analyst Advice  

Directors

Juno Therapeutics Corporate Directors
Hal Barron Director, Ph.D
Richard Klausner Director, Ph.D
Mary Wilderotter Independent Director, Ph.D
Please also check Risk vs Return Analysis. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..